ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

(8-page issue).

January 31, 2003

In Brief: Schmidt Sells OMB On Training Grants, But Weinberger Is The One To Convince

December 21, 1973

Ford To Resubmit Budget Slash Of $125 Million For NCI

January 3, 1975

NIH Limits Salaries On Grants, Contracts ACS Clinical Awards Available For 1995

February 25, 1994

caBIG Architect Kenneth Buetow Resigns

December 16, 2011

Only 10% Of Breast Cancer Patients May Benefit From Contralateral Mastectomy

March 26, 2010